Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
Mi | Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 | 5 | GlobeNewswire (USA) | ||
16.04. | Phathom Pharmaceuticals Appoints Ted Schroeder To Board Of Directors | 2 | RTTNews | ||
16.04. | Phathom Pharmaceuticals beruft Ted Schroeder in den Vorstand | 1 | Investing.com Deutsch | ||
16.04. | Phathom Pharmaceuticals appoints Ted Schroeder to board | 2 | Investing.com | ||
16.04. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.04. | 'SNL' star Kenan Thompson serves up a new campaign for Phathom's Voquezna | 2 | FiercePharma | ||
03.04. | Phathom Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
01.04. | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 90 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
01.04. | Phathom Pharmaceuticals appoints Steven Basta as CEO | 1 | Seeking Alpha | ||
01.04. | Phathom Pharmaceuticals Appoints Steven Basta To Succeed Terrie Curran As President And CEO | 1 | RTTNews | ||
01.04. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
01.04. | Phathom Pharmaceuticals appoints new CEO | 1 | Investing.com | ||
01.04. | Phathom Pharmaceuticals Announces Leadership Succession | 152 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
31.03. | Kenan Thompson kooperiert mit Phathom bei GERD-Behandlung | 1 | Investing.com Deutsch | ||
31.03. | Kenan Thompson partners with Phathom for GERD treatment | 1 | Investing.com | ||
19.03. | Jefferies cuts Phathom Pharmaceuticals target to $13 | 1 | Investing.com | ||
07.03. | H.C. Wainwright maintains $28 target on Phathom Pharma stock | 1 | Investing.com | ||
06.03. | Phathom Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
06.03. | Stifel maintains Buy on Phathom stock with $28 target | 2 | Investing.com | ||
06.03. | Phathom Pharmaceuticals Non-GAAP EPS of -$0.79 beats by $0.29, revenue of $29.7M beats by $4.05M | 2 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TEMPUS AI | 49,570 | 0,00 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 33,290 | 0,00 % | Summit Therapeutics: Überzeugende Daten - BioNTech gibt ebenfalls mächtig Gas | Die Biotech-Gesellschaft Summit Therapeutics, mit einem Börsenwert von gut 20 Milliarden Dollar kein kleines Unternehmen mehr, kann am Mittwoch erneut über vielversprechende Daten zum großen Hoffnungsträger... ► Artikel lesen | |
EVOTEC | 7,114 | -1,44 % | Evotec vor dem Comeback? Warum die Aktie plötzlich wieder gefragt ist | Die Aktie von Evotec schraubte sich im frühen Handel zeitweise um acht Prozent nach oben. Zwar konnte die Aktie dieses Niveau nicht halten. Ist dies dennoch der Beginn einer nachhaltigen Trendwende?... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,570 | 0,00 % | Recursion Pharmaceuticals: Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 | ||
QIAGEN | 37,530 | -0,04 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
ENSYSCE BIOSCIENCES | 3,670 | 0,00 % | Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds | SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 13,530 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) | ||
BIONTECH | 99,70 | -1,68 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 41,170 | 0,00 % | Barclays maintains SpringWorks stock at Overweight, $63 target | ||
DYNE THERAPEUTICS | 10,780 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments | - Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 49,990 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ... | ||
ADMA BIOLOGICS | 21,750 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 30,660 | 0,00 % | Avidity Biosciences Inc Aktie: Routinebericht des Unternehmens | Avidity Biosciences hat die Rekrutierung für die Biomarker-Kohorte der Phase-1/2-FORTITUDE-Studie für Delpacibart Braxlosiran (Del-Brax) abgeschlossen. Diese Studie zielt auf Patienten mit fazioskapulohumeraler... ► Artikel lesen | |
KYMERA THERAPEUTICS | 30,720 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader | Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June... ► Artikel lesen | |
NURIX THERAPEUTICS | 11,640 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions | Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical... ► Artikel lesen |